Contact Us

Close

Contact Spring Bioscience for more information

  • This field is for validation purposes and should be left unchanged.

Introducing PTEN (SP218)!

New test for cancer researchers targets important tumor-suppressor protein Highly sensitive test gives researchers a more sophisticated tool to assess PTEN protein expression in cancer cells PLEASANTON, Ca., September 9, 2013 — As researchers push to develop more customized diagnostics and therapies for solid tumor cancers, they demand increasingly sensitive tests that offer reliable, reproducible […]

Read More ➞

Spring Bioscience to Launch exclusive BRAF V600E Antibody to the Research Market

Ventana signs exclusive licensing agreement for the commercialization of a novel BRAF V600E mutation antibody for cancer detection New assay will strengthen leadership in emerging area of mutation-specific antibodies to address unmet medical needs in cancer Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, has signed an exclusive license agreement with the […]

Read More ➞